Modality
mAb
MOA
SOS1i
Target
MALT1
Pathway
Fibrosis
RBMCL
Development Pipeline
Preclinical
Dec 2017
→ Jan 2030
PreclinicalCurrent
NCT05305024
1,349 pts·MCL
2021-05→2030-01·Terminated
NCT07445911
2,928 pts·MCL
2017-12→TBD·Active
4,277 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-01-083.8y awayInterim· MCL
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
Preclinical
Active
Preclinical
Termina…
Catalysts
Interim
2030-01-08 · 3.8y away
MCL
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05305024 | Preclinical | MCL | Terminated | 1349 | EASI-75 |
| NCT07445911 | Preclinical | MCL | Active | 2928 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| REG-647 | Regeneron | Preclinical | SMN2 |